Sareum (LON:SAR – Get Free Report) posted its quarterly earnings data on Monday. The company reported GBX (2.40) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
Sareum Trading Down 1.6%
Shares of Sareum stock opened at GBX 15 on Tuesday. Sareum has a 52 week low of GBX 11.75 and a 52 week high of GBX 40. The company’s 50-day moving average price is GBX 29.19 and its two-hundred day moving average price is GBX 22.36. The stock has a market cap of £20.96 million, a PE ratio of -3.85 and a beta of -1.08.
About Sareum
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
See Also
- Five stocks we like better than Sareum
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
